| Document |
Document Title |
|
WO/2013/147233A1 |
The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection p...
|
|
WO/2013/139993A1 |
The present invention refers to a modified phalloidin, which may be coupled via the primary group at side chain 7 to a labelling group or a matrix, which may bind with high affinity to filamentous actin (F-actin). The compound and the ma...
|
|
WO/2013/127816A1 |
Herein is reported a method for obtaining a polypeptide by an immobilized metal ion affinity chromatography from a pro-polypeptide that comprise at its N- or C-terminus an metal ion affinity chromatography tag and a protease cleavage sit...
|
|
WO/2013/122061A1 |
The purpose of the present invention is to provide: a peptide having affinity for silicon nitride; the polynucleotide encoding said peptide; an expression vector for the peptide having affinity for silicon nitride; an expression vector f...
|
|
WO/2013/117880A1 |
As shown in Figure 4, substrate (1) has printed areas on it and these areas include a biological molecule which has been printed on the surface using a rotary printing press methods to allow for rapid and high quality printing. The print...
|
|
WO/2013/119061A1 |
The present invention relates to a dosage form for the transdermal delivery of drugs, and to a method for manufacturing same. More specifically, the present invention relates to: a method for manufacturing a drug delivery vector for tran...
|
|
WO/2013/113107A1 |
Methods of stimulating neuron survival, axon growth and/or promoting axon regeneration of a neogenin expressing cell in a subject in need thereof are provided. The methods involve for example, administering to a subject in need thereof a...
|
|
WO/2013/110163A1 |
Compositions for and methods of stimulating a M HC I mediated immune response comprising stimulating MHC I endolysosomal cross presentation in dendritic cells. Stimulation MHC I endolysosomal cross presentation may comprise over-expressi...
|
|
WO/2013/108983A1 |
The present invention relates to a pH-reactive high-density lipoprotein (HDL)-like particle complex, and more specifically, to a high-density lipoprotein-like particle complex comprising apolipoprotein A-I (apoA-I) and a drug trapped the...
|
|
WO/2013/081037A1 |
The present invention relates to a peptide which contains an amino acid sequence consisting of 14 to 18 amino acid residues and capable of binding to human IgA, and an analysis or purification method for the human IgA which uses the pept...
|
|
WO/2013/078091A1 |
The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Zm-[Gly-X-Y]n- LGly -X-Y-[Gly-X-Y]n; wherein L is one or more detectable moieties and/or biologically active compounds; S is one or more ...
|
|
WO/2013/075600A1 |
Disclosed are a polyethylene glycol-modified polypeptide and the use thereof in the preparation of drugs for tumour treatment. The polypeptide has the function of inhibiting tumour angiogenesis and is an integrin blocker with affinity an...
|
|
WO/2013/071440A1 |
Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering ...
|
|
WO/2013/065782A1 |
The invention provides a protein-immobilizing solid phase and a polynucleotide-immobilizing solid phase that make it possible to recover nucleic acid efficiently from the solid phase, and an efficient nucleic acid recovery method. In one...
|
|
WO/2013/067509A1 |
Methods and devices for purification of different cell components from the same sample are provided.
|
|
WO/2013/066106A1 |
The present invention relates to a method for preparaing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using a...
|
|
WO/2013/062105A1 |
Provided is an affinity carrier having a low pressure loss and a high binding capacity, even when the linear flow rate of a solution passing through the carrier is fast. Also provided is a silica spherical body having (a) according to la...
|
|
WO/2013/056377A1 |
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.
|
|
WO/2012/154735A9 |
The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for u...
|
|
WO/2013/039190A1 |
The purpose of the present invention is to provide a polypeptide-containing polymer that can be used to manufacture an antimicrobial fiber. The purpose of the present invention is also to provide a method for polypeptide immobilization o...
|
|
WO/2013/038158A1 |
The disclosure relates to a magnetic particle comprising: a ligand that specifically binds an intracellular antigen, a cell membrane penetrating cationic peptide and a peptide comprising an amino acid sequence that is adapted to interact...
|
|
WO/2013/033838A1 |
Liposomal formulations of cationic peptides and anionic liposomes are provided. The liposomal formulations comprise a diagnostic or therapeutic cationic peptide associated with liposomes comprising one or more anionic lipids. Methods of ...
|
|
WO/2012/173422A9 |
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-p...
|
|
WO/2012/172347A9 |
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample o...
|
|
WO/2013/029180A1 |
It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective a...
|
|
WO/2013/029182A1 |
It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutical...
|
|
WO/2013/029472A1 |
Provided is a composition for extracting unrelated circulating nucleated cells from the peripheral blood of a diseased animal model, comprising the composition kit. The composition consists of the following ingredients: buffer solution, ...
|
|
WO/2013/033359A1 |
Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analy...
|
|
WO/2013/027796A1 |
Provided is a peptide capable of binding to human IgG specifically or selectively. A peptide characterized by comprising an amino acid sequence represented by formula (I): (X1-3)-C-(X2)-H-R-G-(Xaa1)-L-V-W-C-(X1-3) (wherein Xs independent...
|
|
WO/2007/025388A9 |
Single-domain antibodies that bind pro-apoptotic proteins Bax and caspase-3 are identified and isolated. These single-domain antibodies may be used to modulate the activity of Bax and caspase-3, thereby modulating the symptoms and steps ...
|
|
WO/2013/025052A2 |
The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer which shows excellent water dispersion, and has biological activity so as to be used as a stimulus-reactive...
|
|
WO/2013/018880A1 |
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly...
|
|
WO/2013/010225A1 |
The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the na...
|
|
WO/2013/002449A1 |
Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epito...
|
|
WO/2012/177775A1 |
The invention provides methods for delivery of payloads to targets in samples using non-sterically hindered complexes. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provi...
|
|
WO/2012/172342A2 |
A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemok...
|
|
WO/2012/172337A2 |
A method for treating cardiovascular disease comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/172336A2 |
A method for treating inflammatory skin disease comprises applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine ...
|
|
WO/2012/172339A2 |
A method for treating inflammatory arthritis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/172343A2 |
A method for treating primary sclerosing cholangitis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding...
|
|
WO/2012/171429A1 |
Disclosed are a polyethylene glycol-interferon conjugate, a preparation method thereof, and a pharmaceutical composition containing a therapeutically effective amount of the interferon conjugate and use thereof in the preparation of anti...
|
|
WO/2012/172346A2 |
A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ...
|
|
WO/2012/172344A2 |
A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of s...
|
|
WO/2012/172340A2 |
A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent c...
|
|
WO/2012/172345A2 |
A method for treating an allergic condition comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine rece...
|
|
WO/2004/070015A9 |
|
|
WO/2012/159171A1 |
The present invention relates to complexes of silica-containing materials and peptide linkers for the capture of biological and chemical entities. In particular, the present invention relates to the use of complexes of silica-containing ...
|
|
WO/2012/159170A1 |
The present invention relates to methods of capturing biological and chemical entities indirectly or directly bound to a peptide linker. In particular, the present invention relates to the use of silica-containing materials to capture bi...
|
|
WO/2012/157339A1 |
This growth factor anchoring type bone graft material is characterized in that growth factor containing collagen-binding sites, which contains growth factor receptor agonist peptides and collagen-binding peptides, is bonded to a bone gra...
|
|
WO/2012/158445A1 |
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal...
|
